Turn Therapeutics Inc. has released a corporate presentation outlining its development of first-in-class, precision, non-systemic immunomodulation therapies targeting IL-36 and key downstream cytokines for inflammatory diseases, with an initial focus on moderate to severe eczema. The company’s lead candidate, GX-03, is a topical IL-36/IL-31/IL-4 inhibitor currently in a Phase 2 randomized controlled trial for moderate to severe eczema, with topline results expected in mid-2026. GX-03’s active pharmaceutical ingredient is classified as a New Chemical Entity in the United States and is supported by strong patent coverage through 2037. More than 200,000 applications of GX-03 have been reported with no adverse events. Additional indications in the pipeline include onychomycosis and psoriasis. Turn Therapeutics also highlights its PermaFusion delivery platform, which enables stable, emulsifier-free dispersion of active ingredients. Phase 1-level safety data from a 53-patient study reported no significant adverse reactions. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief on February 09, 2026, and is solely responsible for the information contained therein.